03/03/2026
๐จ Major Regulatory Alert:
CDSCO is moving toward a 'Notified Body' model for drug audits!
By partnering with QCI and planning a recruitment drive for 1,500 new personnel, the DCGI is aiming to put Indiaโs regulatory oversight on par with the US FDA and EMA. Hereโs what this means for manufacturing compliance.
Key Takeaways from the Post :
Engagement of Notified Bodies: CDSCO will formally involve third-party "notified bodies" certified by the QCI to conduct various drug regulatory audits.
Shift from Government-Only Audits: Traditionally, audits were restricted to drug inspectors from the CDSCO or State Regulatory Authorities. This move opens the door for accredited private/third-party entities to participate in the oversight process.
Modeled on Global Standards: The framework is inspired by the European Medicines Agency (EMA) model, where notified bodies evaluate medical devices and grant certifications (like the CE mark) before products enter the market.
Massive Manpower Expansion: Alongside outsourcing audits, CDSCO plans to recruit approximately 1,500 new personnel to strengthen its internal scientific review capacity and reduce dependence on external subject expert committees.
Approval Status: The government has granted "in-principle" approval, and the CDSCO is currently in the final stages of formalizing the engagement framework with the QCI.
Why is CDSCO collaborating with QCI ?
The collaboration is driven by a need to modernize Indiaโs regulatory infrastructure and address several critical bottlenecks:
1. Addressing Manpower and Capacity Gaps
2. Improving Audit Coverage and Frequency
3. Enhancing Technical Expertise
4. Building "Institutional Memory"
5. Achieving Global Parity
The ultimate goal is to make Indiaโs regulatory system as robust as the US FDA or the EMA. By adopting the "notified body" system used in Europe, India aims to reinforce global confidence in the quality and safety of Indian-made pharmaceuticals, which is vital for the country's status as the "pharmacy of the world."
CDSCO soon to engage QCI certified notified bodies to augment drug regulatory audit capacity: DCGI
